Biogen (BIIB) Change in Taxes (2014 - 2026)
Biogen (BIIB) recorded quarterly Change in Taxes of $18.4 million in Q1 2026, up 109.48% quarter-over-quarter from -$194.0 million in Q4 2025, and down 73.37% on a YoY basis from $69.1 million in Q1 2025.
Biogen (BIIB) Change in Taxes (2014 - 2026) Analysis & Trends
Biogen's Change in Taxes history runs 13 years deep, the most recent figure standing at $18.4 million for Q1 2026.
- In Q1 2026, Change in Taxes fell 73.37% year-over-year to $18.4 million; the TTM figure through Mar 2026 stood at -$1.0 billion (down 773.43% YoY), while the FY2025 annual figure was -$958.1 million, down 1320.51% from the prior year.
- Change in Taxes was $18.4 million for Q1 2026 at Biogen, up from -$194.0 million in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $101.9 million in Q1 2022 to a low of -$603.8 million in Q2 2025.
- Historically, Change in Taxes has averaged -$76.6 million across 5 years, with a median of -$32.4 million in 2023.
- Biggest YoY gain for Change in Taxes was 3240.91% in 2025; the steepest drop was 10878.18% in 2025.
- A 5-year view of Change in Taxes shows it stood at -$42.1 million in 2022, then tumbled by 337.53% to -$184.2 million in 2023, then surged by 108.9% to $16.4 million in 2024, then sank by 1282.93% to -$194.0 million in 2025, then jumped by 109.48% to $18.4 million in 2026.
- The last three Change in Taxes figures came in at $18.4 million (Q1 2026), -$194.0 million (Q4 2025), and -$229.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 411.19 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 18.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.40 Mn |
| Mar 31, 2026 | 18.40 Mn |
| Dec 31, 2025 | -194.00 Mn |
| Dec 31, 2025 | -194.00 Mn |
| Sep 30, 2025 | -229.40 Mn |
| Sep 30, 2025 | -229.40 Mn |
| Jun 30, 2025 | -603.80 Mn |
| Jun 30, 2025 | -603.80 Mn |
| Mar 31, 2025 | 69.10 Mn |
| Mar 31, 2025 | 69.10 Mn |
| Dec 31, 2024 | 16.40 Mn |
| Dec 31, 2024 | 16.40 Mn |
| Sep 30, 2024 | 69.80 Mn |
| Sep 30, 2024 | 69.80 Mn |
| Jun 30, 2024 | -5.50 Mn |
| Jun 30, 2024 | -5.50 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Dec 31, 2023 | -184.20 Mn |
| Dec 31, 2023 | -184.20 Mn |